News from halozyme therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 19, 2014, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission, acting on the recommendation from the Committee for...

Dec 17, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE™ Technology

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen...

Dec 12, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at...

Dec 03, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York on Wednesday,...

Nov 25, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014...

Nov 10, 2014, 16:05 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Reports Third Quarter 2014 Financial Results

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2014. Financial...

Nov 05, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday,...

Nov 03, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme to Host Third Quarter 2014 Financial Results Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10,...

Oct 20, 2014, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved new contract...

Oct 09, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Podium Presentation On PEGPH20 At The New York Academy Of Sciences

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced an oral presentation on the pharmacology of PEGPH20 at the New York Academy of...

Oct 07, 2014, 08:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the issuance of U.S. Patent No. 8,846,034 claiming methods for selecting a...

Oct 03, 2014, 07:45 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for...

Sep 18, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on...

Sep 03, 2014, 08:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation...

Aug 11, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Reports Second Quarter 2014 Financial Results

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2014. Financial...

Aug 04, 2014, 16:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme to Host second Quarter 2014 Financial Results Conference Call

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11,...

Jul 22, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial...

Jun 25, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera® SC in Europe has triggered a $5...

Jun 17, 2014, 16:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the JMP Securities 2014 Healthcare Conference in New York, NY, on Tuesday,...

Jun 15, 2014, 15:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th...